| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2026―Mar―20 |
Dual SARS-COV-2 Mpro and PLpro inhibitors based on an 8-((phenylamino)methyl)-[1,4]dioxinoquinolin-7-one scaffold |
Larysa V. Yevsieieva, Pavlo Trostyanko, Anna Geleverya, Alexander Kyrychenko, Volodymyr V. Ivanov, Volodymyr Fetyukhin, et al. (+2) Sergiy M. Kovalenko, Oleg N. Kalugin |
| 2 |
[GO] |
2025―Jan―21 |
Molecular docking against Covid-19 and HIV, and the role of catalysis in stereoselective cycloaddition reactions: A theoretical investigation of TiCl4-promoted reactions between cyclopenta-1,3-diene and benzyl acrylate/benzyl 2-fluoroacrylate |
Khadija El Idrissi, Abdellah Zeroual, Hocine Garmes |
| 3 |
[GO] |
2023―Oct―06 |
In silico investigations on the repurposing of antivirals for Covid-19 and pharmacophore modelling |
Vinod P Raphael, K.S. Shaju, T.K. Bindu, A. Sini |
| 4 |
[GO] |
2023―Oct―06 |
Insight into a new discovery of SARS-CoV-2 inhibitor activated through Chloroquine derivatives |
Mohammed Salah, Oumaima El Alaoui El Abdallaoui, Abdellah Zeroual, Nivedita Acharjee, Mohammed El idrissi |
| 5 |
[GO] |
2022―Oct―13 |
Gallic acid-butyramide monohydrate cocrystal: Crystal growth, Structural insights, Theoretical calculations and Molecular docking studies against COVID-19 main protease |
K.L. Jyothi, M.K. Hema, Karthik Kumara, N.K. Lokanath |
|
